Loading the security overview…
Where the tokens are
None held
3 tokenized versions from 3 issuers
See every versionNo venues yet
No vault or pool we index takes these tokens.
PerpsNo markets
No Hyperliquid venue lists a AMGN perp.
Where the AMGN tokens are
3 tokens · 11 chains · 1 unreadAMGNxxStocks155.17K
BNB17.35K
HyperEVM17.35K
Ink17.35K
Arbitrum17.35K
X Layer17.35K
Optimism17.35K
Ethereum17.35K
Mantle16.89K
Solana16.85K
BNB17.35KHyperEVM17.35KInk17.35KArbitrum17.35KX Layer17.35KOptimism17.35KEthereum17.35KMantle16.89KSolana16.85KMinted supply on each chain, read from the chain: it includes tokens the issuer holds unsold, so it is not what investors hold.
Token data table
| Token | Chain | Supply | 24h volume | Liquidity |
|---|---|---|---|---|
| AMGNx xStocks | Solana | 16.85K | — | — |
| AMGNx xStocks | BNB | 17.35K | — | — |
| AMGNx xStocks | TON | — | — | — |
| AMGNx xStocks | HyperEVM | 17.35K | — | — |
| AMGNx xStocks | Ink | 17.35K | — | — |
| AMGNx xStocks | Arbitrum | 17.35K | — | — |
| AMGNx xStocks | Mantle | 16.89K | — | — |
| AMGNx xStocks | X Layer | 17.35K | — | — |
| AMGNx xStocks | Optimism | 17.35K | — | — |
| AMGNx xStocks | Ethereum | 17.35K | — | — |
| AMGNon Ondo | Ethereum | 9.02 | — | — |
| AMGNon Ondo | BNB | 2.83 | — | — |
| AMGNon Ondo | Solana | 3.31 | — | — |
| rAMGN Reality | Arbitrum | 34.15 | — | — |
| rAMGN Reality | Morph | 0 | — | — |
Key statistics
technicals as of Oct 2, 2026- Market cap
- $220.18B
- P/E
- 25.2EPS $16.17
- 52-week range
- $270.67 – $447.03price at 75% of range
- Volume
- 1.68Maverage day 2.91M
- Previous close
- $407.27
- P/S
- 5.8
- P/B
- 18.8
- Dividend yield
- 2.40%$10.08 a year
- Next ex-dividend
- —
- Next earnings
- Nov 3after the close
- Beta
- 0.2890 days, against SPY
- RSI (14)
- 47.7as of Oct 2
Figures describe Amgen shares, not any token.
Every tokenized version
Search and filter all tokensEach row is one issuer’s token for Amgen, with the chains it is deployed on. A bold chain is one where these wallets hold a balance. Tokens are not shares: no issuer in the registry publishes a shares-per-token ratio, so a balance is counted one per share and marked where that assumption is doing work.
About Amgen Inc
amgen.comAmgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
- Type
- Common stock
- Sector
- Healthcare › Biotechnology
- Exchange
- Nasdaq
- Listed since
- Jun 17, 1983
- Shares outstanding
- 540.63M
- Employees
- 31,500
Themes
Biotech - Drug Development › Rare Disease TherapeuticsBiotech - Drug Development › Immunology & AutoimmuneHealthcare - Oncology › Immunotherapy & Immuno-Oncology
Companies sharing these themesAs the market data provider names it. Where that differs from the issuers’ name for the security, both are shown so the difference is visible.